CO6180424A2 - Inhibodores espiro cetona de acetil-coa carboxilasa - Google Patents
Inhibodores espiro cetona de acetil-coa carboxilasaInfo
- Publication number
- CO6180424A2 CO6180424A2 CO09054954A CO09054954A CO6180424A2 CO 6180424 A2 CO6180424 A2 CO 6180424A2 CO 09054954 A CO09054954 A CO 09054954A CO 09054954 A CO09054954 A CO 09054954A CO 6180424 A2 CO6180424 A2 CO 6180424A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- haloalkyl
- halo
- phenyl
- alkoxy
- Prior art date
Links
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 11
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 8
- 125000005843 halogen group Chemical group 0.000 abstract 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 8
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 7
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 6
- -1 C1-3 alkyl-OH Chemical group 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000006594 (C1-C3) alkylsulfony group Chemical group 0.000 abstract 2
- OXRRHYRRQWIHIV-UHFFFAOYSA-N 2,3-dihydro-1h-pyridin-6-one Chemical compound O=C1NCCC=C1 OXRRHYRRQWIHIV-UHFFFAOYSA-N 0.000 abstract 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 abstract 1
- NZHIIDNOLFOHSG-UHFFFAOYSA-N 2,3-dihydropyridine Chemical compound C1CN=CC=C1 NZHIIDNOLFOHSG-UHFFFAOYSA-N 0.000 abstract 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
1.- Un compuesto, que tiene a fórmulao una sal farmacéuticamente aceptable del mismo, en la que: (a) R1 es H, OH, halo, ciano, alquilo C1-3, alcoxi C1-3, haloalquilo C1-3, haloalcoxi C1-3, alquilsulfonil C1-3-, -CO(O)H, -C(O)Oalquilo C1-3 o fenilo, en el que dicho fenilo está opcionalmente sustituido con uno a cinco R10; (b) cada R10 es independientemente OH, halo, ciano, alquilo C1-3, alcoxi C1-3, haloalquilo C1-3 o haloalcoxi C1-3; (c) cada uno de R2 y R3 es independientemente H, OH, halo, ciano, alquilo C1-3, alcoxi C1-3, haloalquilo C1-3, haloalcoxi C1-3, alquilsulfonil C1-3-, -CO(O)H, - C(O)Oalquilo C1-3, -C(O)NR11R12 o fenilo, en el que dicho fenilo está opcionalmente sustituido con uno a cinco R10; (d) R11 y R12 se toman por separado y cada uno es independientemente H o alquilo C1-3, o R11 y R12 se tornan juntos con el nitrógeno al que están unidos, para formar un heterocicloalquilo de 4-7 miembros; (e) R4 es H, halo, ciano, alquilo C1-3 o haloalquilo C1-3; (f) R6 se toma por separado y es H, OH, halo, alquilo C1-3, alcoxi C1-3, haloalquilo C1-3 o haloalcoxi C1-3; (g) R7 se toma por separado y es H, OH, halo, alquilo C1-3, alcoxi C1-3, haloalquilo C1-3 o haloalcoxi C1-3;(h) R5 se toma por separado y es un heteroarilo de 4-7 miembros opcionalmente sustituido con halo, alquilo C1-3, alcoxi C1-3, alquil C1-3-OH, haloalquilo C1-3 o C1-3; o (i) R5 se toma junto con R6 o R7, y con el fenilo al que R5 y R6 o R7 están unidos, para formar un radical heterocíclico policíclico, con un anillo que tiene nitrógeno en el que al menos un átomo de nitrógeno está unido a un átomo de carbono de dicho fenilo, donde el anillo que tiene nitrógeno está opcionalmente condensado con ciclohexeno, 5,6-dihidro-piridina o 5,6-dihidro-1H-piridin-2-ona, y donde el anillo que tiene nitrógeno está opcionalmente sustituido independientemente con uno a dos oxo, halo, alquilo C1-3, alcoxi C1-3, alquil C1-3-OH, haloalquilo C1-3, haloalcoxi C1-3, heteroarilo de 4-7 miembros, heterocicloalquilo de 4-7 miembros o fenilo, en el que dicho fenilo está opcionalmente sustituido con uno a cinco R10, con la condición de que R5 no se tome junto con R6 para formar un benzotriazolilo o un benzooxadiazolilo y con la condición de que R5 no se tome junto con R7 para formar un benzooxadiazolilo; y ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86177906P | 2006-11-29 | 2006-11-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6180424A2 true CO6180424A2 (es) | 2010-07-19 |
Family
ID=39126209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09054954A CO6180424A2 (es) | 2006-11-29 | 2009-05-28 | Inhibodores espiro cetona de acetil-coa carboxilasa |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20090270435A1 (es) |
| EP (1) | EP2097420B1 (es) |
| JP (1) | JP2010511035A (es) |
| KR (1) | KR20090083956A (es) |
| CN (1) | CN101541809A (es) |
| AP (1) | AP2009004880A0 (es) |
| AT (1) | ATE552262T1 (es) |
| AU (1) | AU2007326950B2 (es) |
| BR (1) | BRPI0721053A2 (es) |
| CA (1) | CA2670422C (es) |
| CO (1) | CO6180424A2 (es) |
| CR (1) | CR10831A (es) |
| EA (1) | EA200900613A1 (es) |
| EC (1) | ECSP099371A (es) |
| IL (1) | IL198779A0 (es) |
| MA (1) | MA30932B1 (es) |
| MX (1) | MX2009005604A (es) |
| NO (1) | NO20091889L (es) |
| RS (1) | RS20090249A (es) |
| SV (1) | SV2009003281A (es) |
| TN (1) | TN2009000204A1 (es) |
| WO (1) | WO2008065508A1 (es) |
| ZA (1) | ZA200903268B (es) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008205642B2 (en) * | 2007-01-12 | 2013-06-06 | Msd K.K. | Spirochromanon derivatives |
| PE20081559A1 (es) * | 2007-01-12 | 2008-11-20 | Merck & Co Inc | DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA |
| CN100550853C (zh) * | 2007-01-25 | 2009-10-14 | 华为技术有限公司 | 一种基于输出队列的流控实现方法及装置 |
| DE102007028521A1 (de) * | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | Indazolamidderivate |
| EP2297164A1 (en) * | 2008-05-28 | 2011-03-23 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| US8318762B2 (en) | 2008-05-28 | 2012-11-27 | Pfizer Inc. | Pyrazolospiroketone acetyl-CoA carboxylase inhibitors |
| US8524730B2 (en) * | 2008-07-04 | 2013-09-03 | Msd K.K. | Spirochromanone carboxylic acids |
| CA2730493A1 (en) | 2008-07-14 | 2010-01-21 | Cropsolution, Inc. | Modulators of acetyl-coenzyme a carboxylase and methods of use thereof |
| DE102008038222A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | Indazol-5-carbonsäurehydrazid-derivate |
| EP2184276A1 (en) | 2008-11-07 | 2010-05-12 | Universite Paul Cezanne Aix-Marseille Iii | Process to prepare new substituted 1H-Benzo(d) imidazol-2(3h)-Ones, New intermediates and their use as bace 1 inhibitors |
| CU24077B1 (es) * | 2009-11-10 | 2015-03-30 | Pfizer | DERIVADOS DE N1-PIRAZOLOESPIROCETONA ÚTILES COMO INHIBIDORES DE ACETIL-CoA CARBOXILASA |
| US20120225900A1 (en) * | 2009-11-10 | 2012-09-06 | Pfizer Inc. | N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| ME02330B (me) | 2010-03-19 | 2016-06-20 | Pfizer | Derivati 2,3-dihidro-1h-inden-1-il-2,7-diazaspir0[3.6]nonana i njihova upotreba kao antagonista ili inverznih agonista grelinskog receptora |
| WO2011140425A1 (en) | 2010-05-06 | 2011-11-10 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| HRP20161178T1 (hr) | 2010-09-30 | 2016-11-04 | Pfizer Inc. | N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE |
| CA2815169C (en) | 2010-10-29 | 2015-10-06 | Pfizer Inc. | N1/n2-lactam acetyl-coa carboxylase inhibitors |
| RU2634900C2 (ru) | 2011-02-02 | 2017-11-08 | Вертекс Фармасьютикалз Инкорпорейтед | Спироциклические пирролопиразин(пиперидин)амиды в качестве модуляторов ионных каналов |
| JP5940562B2 (ja) * | 2011-02-18 | 2016-06-29 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | イオンチャネルのモジュレーターとしてのクロマン−スピロ環式ピペリジンアミド |
| WO2012125613A1 (en) | 2011-03-14 | 2012-09-20 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
| ME02312B (me) | 2011-04-22 | 2016-06-20 | Pfizer | DERIVATI PIRAZOLOSPIROKETONA, NAMIJENJENI UPOTREBI KAO INHIBITORI ACETIL-CoA-KARBOKSILAZE |
| JP5955954B2 (ja) | 2011-07-08 | 2016-07-20 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | ２−アミノ−５−シアノ−ｎ，３−ジメチルベンズアミドを製造する方法 |
| WO2013011402A1 (en) | 2011-07-15 | 2013-01-24 | Pfizer Inc. | Gpr 119 modulators |
| CN103732578B (zh) | 2011-07-22 | 2015-08-12 | 辉瑞大药厂 | 喹啉基胰高血糖素受体调节剂 |
| MX348548B (es) | 2011-08-18 | 2017-06-19 | Nippon Shinyaku Co Ltd | Derivado heterociclico y farmaceutico. |
| WO2013030713A1 (en) | 2011-08-31 | 2013-03-07 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds |
| GEP201706656B (en) | 2011-11-11 | 2017-04-25 | Pfizer | 2-thiopyrimidinones |
| HK1206735A1 (en) | 2012-04-06 | 2016-01-15 | 辉瑞公司 | Diacylglycerol acyltransferase 2 inhibitors |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| WO2013164730A1 (en) | 2012-05-04 | 2013-11-07 | Pfizer Inc. | Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2. |
| US9260455B2 (en) | 2012-09-20 | 2016-02-16 | Pfizer Inc. | Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| WO2014091352A1 (en) | 2012-12-11 | 2014-06-19 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
| WO2014097038A1 (en) | 2012-12-19 | 2014-06-26 | Pfizer Inc. | CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS |
| EP2956458B1 (en) | 2013-02-13 | 2017-08-09 | Pfizer Inc | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| JP6348582B2 (ja) | 2013-10-09 | 2018-06-27 | ファイザー・インク | プロスタグランジンｅｐ３受容体の拮抗薬 |
| RS57384B1 (sr) | 2014-03-17 | 2018-09-28 | Pfizer | Inhibitori diacilglicerol aciltransferaze 2 za upotrebu u tretmanu metaboličkih i srodnih poremećaja |
| LT3126330T (lt) | 2014-04-04 | 2019-04-25 | Pfizer Inc. | Bicikliniai kondensuoti heteroarilo arba arilo junginiai, ir jų panaudojimas kaip irak4 inhibitorių |
| AP2016009493A0 (en) | 2014-04-10 | 2016-10-31 | Pfizer | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES |
| WO2016092413A1 (en) | 2014-12-10 | 2016-06-16 | Pfizer Inc. | Indole and indazole compounds that activate ampk |
| JP2017538769A (ja) | 2014-12-22 | 2017-12-28 | ファイザー・インク | プロスタグランジンｅｐ３受容体の拮抗薬 |
| WO2016178113A1 (en) | 2015-05-05 | 2016-11-10 | Pfizer Inc. | 2-thiopyrimidinones |
| WO2016193844A1 (en) | 2015-05-29 | 2016-12-08 | Pfizer Inc. | Novel heterocyclic compounds as inhibitors of vanin-1 enzyme |
| ES2924371T3 (es) | 2015-06-17 | 2022-10-06 | Pfizer | Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa |
| WO2016203335A1 (en) | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
| US20180230127A1 (en) | 2015-08-13 | 2018-08-16 | Pfizer Inc. | Bicyclic-Fused Heteroaryl Or Aryl Compounds |
| RS61719B1 (sr) | 2015-08-27 | 2021-05-31 | Pfizer | Biciklična fuzionisana hetaroaril ili aril jedinjenja kao modulatori irak4 |
| WO2017037567A1 (en) | 2015-09-03 | 2017-03-09 | Pfizer Inc. | Regulators of frataxin |
| WO2017051294A1 (en) | 2015-09-24 | 2017-03-30 | Pfizer Inc. | N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors |
| EP3353182A1 (en) | 2015-09-24 | 2018-08-01 | Pfizer Inc | Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors |
| BR112018003489A2 (pt) | 2015-09-24 | 2018-09-25 | Pfizer | n-[2-(2-amino-6,6-dissubstituído-4,4a,5,6-tetra-hidropirano[3,4-d][1,3]tiazin-8a(8h)-il)-1,3-tiazol-4-il]amidas |
| MX376072B (es) | 2015-12-29 | 2025-03-07 | Pfizer | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa |
| CN109476645A (zh) | 2016-07-14 | 2019-03-15 | 辉瑞大药厂 | 作为vanin-1酶抑制剂的新的嘧啶甲酰胺 |
| AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| WO2019133445A1 (en) | 2017-12-28 | 2019-07-04 | Inception Ibd, Inc. | Aminothiazoles as inhibitors of vanin-1 |
| CN108658938B (zh) * | 2018-06-15 | 2021-03-23 | 上海现代制药股份有限公司 | 一种甲磺酸达比加群酯工艺杂质的合成方法 |
| CN108774242B (zh) * | 2018-08-22 | 2020-10-27 | 牡丹江医学院 | 一种防治冠心病的药物及其制备方法 |
| WO2020044266A1 (en) | 2018-08-31 | 2020-03-05 | Pfizer Inc. | Combinations for treatment of nash/nafld and related diseases |
| CN109400618B (zh) * | 2018-11-09 | 2021-08-10 | 中国药科大学 | 一种色满衍生物及其制备方法和应用 |
| WO2020102575A1 (en) | 2018-11-16 | 2020-05-22 | Inception Ibd, Inc. | Heterocyclic aminothiazoles and uses thereof |
| CN109809992A (zh) * | 2019-02-16 | 2019-05-28 | 安徽华胜医药科技有限公司 | 一种2-（2-氟-3-甲氧基苯基）-2-羟基乙酸乙酯的合成方法 |
| WO2020234726A1 (en) | 2019-05-20 | 2020-11-26 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| CN110128347A (zh) | 2019-06-17 | 2019-08-16 | 韶远科技（上海)有限公司 | 一种1-甲基-1h-吲唑-6-甲酸的合成方法 |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| CN119874775A (zh) | 2020-02-07 | 2025-04-25 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| CN114437096B (zh) * | 2020-11-06 | 2025-09-12 | 上海医药集团股份有限公司 | 一种螺杂环类化合物、其制备方法及应用 |
| CN119137124A (zh) | 2022-03-09 | 2024-12-13 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| US20250250269A1 (en) | 2022-04-14 | 2025-08-07 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2024118524A1 (en) | 2022-11-28 | 2024-06-06 | Cerevel Therapeutics, Llc | Azaindole compounds and their use as phosphodiesterase inhibitors |
| EP4634180A1 (en) | 2022-12-15 | 2025-10-22 | Gasherbrum Bio, Inc. | Salts and solid forms of a compound having glp-1 agonist activity |
| TW202530207A (zh) * | 2023-08-16 | 2025-08-01 | 智擎生技製藥股份有限公司 | Ｍｔａ協同性的ｐｒｍｔ５抑制劑 |
| WO2025133948A1 (en) * | 2023-12-21 | 2025-06-26 | Pfizer Inc. | Acetyl coa-carboxylase (acc) inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL96507A0 (en) * | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
| WO1996039140A1 (en) * | 1995-06-06 | 1996-12-12 | Merck & Co., Inc. | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS |
| AU2001289831A1 (en) * | 2000-09-06 | 2002-03-22 | Bayer Aktiengesellschaft | Medicaments against viral infections |
| JPWO2004092179A1 (ja) * | 2003-04-14 | 2006-07-06 | 日本曹達株式会社 | スピロ誘導体、製造法および抗酸化薬 |
| JP2005119987A (ja) * | 2003-10-15 | 2005-05-12 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
| WO2006040329A1 (en) * | 2004-10-12 | 2006-04-20 | Novo Nordisk A/S | 1 ibeta- hydroxysteroid dehydrogenase type 1 active spiro compounds |
| US20090215742A1 (en) * | 2005-05-03 | 2009-08-27 | Pfizer, Inc. | Amide resorcinol compounds |
| US7935712B2 (en) * | 2005-07-19 | 2011-05-03 | Merck Sharp & Dohme Corp. | Spirochromanone derivatives as acetyl coenzyme A carboxylase (ACC) inhibitors |
-
2007
- 2007-11-16 AP AP2009004880A patent/AP2009004880A0/xx unknown
- 2007-11-16 AT AT07825738T patent/ATE552262T1/de active
- 2007-11-16 CN CNA2007800442537A patent/CN101541809A/zh active Pending
- 2007-11-16 BR BRPI0721053-1A patent/BRPI0721053A2/pt not_active IP Right Cessation
- 2007-11-16 CA CA2670422A patent/CA2670422C/en not_active Expired - Fee Related
- 2007-11-16 JP JP2009538803A patent/JP2010511035A/ja active Pending
- 2007-11-16 WO PCT/IB2007/003639 patent/WO2008065508A1/en not_active Ceased
- 2007-11-16 MX MX2009005604A patent/MX2009005604A/es not_active Application Discontinuation
- 2007-11-16 AU AU2007326950A patent/AU2007326950B2/en not_active Expired - Fee Related
- 2007-11-16 US US12/514,596 patent/US20090270435A1/en not_active Abandoned
- 2007-11-16 EP EP07825738A patent/EP2097420B1/en active Active
- 2007-11-16 EA EA200900613A patent/EA200900613A1/ru unknown
- 2007-11-16 KR KR1020097013481A patent/KR20090083956A/ko not_active Ceased
- 2007-11-16 RS RSP-2009/0249A patent/RS20090249A/sr unknown
-
2009
- 2009-05-12 ZA ZA200903268A patent/ZA200903268B/xx unknown
- 2009-05-14 IL IL198779A patent/IL198779A0/en unknown
- 2009-05-14 NO NO20091889A patent/NO20091889L/no not_active Application Discontinuation
- 2009-05-22 TN TNP2009000204A patent/TN2009000204A1/fr unknown
- 2009-05-28 CO CO09054954A patent/CO6180424A2/es not_active Application Discontinuation
- 2009-05-28 CR CR10831A patent/CR10831A/es not_active Application Discontinuation
- 2009-05-29 EC EC2009009371A patent/ECSP099371A/es unknown
- 2009-05-29 MA MA31936A patent/MA30932B1/fr unknown
- 2009-05-29 SV SV2009003281A patent/SV2009003281A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101541809A (zh) | 2009-09-23 |
| MX2009005604A (es) | 2009-06-08 |
| EA200900613A1 (ru) | 2009-10-30 |
| JP2010511035A (ja) | 2010-04-08 |
| CA2670422A1 (en) | 2008-06-05 |
| MA30932B1 (fr) | 2009-11-02 |
| WO2008065508A1 (en) | 2008-06-05 |
| TN2009000204A1 (fr) | 2010-10-18 |
| RS20090249A (sr) | 2010-06-30 |
| CR10831A (es) | 2009-06-18 |
| ECSP099371A (es) | 2009-06-30 |
| CA2670422C (en) | 2011-09-06 |
| AU2007326950A1 (en) | 2008-06-05 |
| IL198779A0 (en) | 2010-02-17 |
| BRPI0721053A2 (pt) | 2014-07-29 |
| KR20090083956A (ko) | 2009-08-04 |
| SV2009003281A (es) | 2010-08-17 |
| ATE552262T1 (de) | 2012-04-15 |
| NO20091889L (no) | 2009-06-17 |
| EP2097420A1 (en) | 2009-09-09 |
| AU2007326950B2 (en) | 2010-10-14 |
| EP2097420B1 (en) | 2012-04-04 |
| AP2009004880A0 (en) | 2009-06-30 |
| ZA200903268B (en) | 2010-07-28 |
| US20090270435A1 (en) | 2009-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6180424A2 (es) | Inhibodores espiro cetona de acetil-coa carboxilasa | |
| CO5700721A2 (es) | Compuestos de quinolina sustituidos | |
| AR073706A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR050540A1 (es) | Derivados de adamantilamida triciclica como inhibidores de deshidrogenasa 11- beta hidroxiesteroide | |
| AR064355A1 (es) | Herbicidas derivados de isoxazol | |
| PE20091381A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR063653A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR088534A1 (es) | Composiciones plaguicidas y procesos relacionados con dichas composiciones | |
| AR107307A2 (es) | Composición colectora útil para beneficiar a una mena mineral que contiene sulfuro | |
| AR091710A1 (es) | Composiciones pesticidas y procesos relacionados con las mismas | |
| AR078397A1 (es) | Compuestos heterociclicos antivirales | |
| CO6270320A2 (es) | Derivados de piperidina utiles como antagonistas del receptor orexina | |
| AR061548A1 (es) | 3-aminopirrolidino-4-lactamas sustituidas como inhibidoras de dipeptidilpeptidasa iv (dpp-iv), composiciones farmaceuticas que las comprenden y el uso de las mismas en el tratamiento de la diabetes ii. | |
| AR058776A1 (es) | Compuesto de piridina condensado | |
| CO6251243A2 (es) | Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c | |
| CO6311055A2 (es) | Composiciones pesticidas con al menos cuatro estructuras de anillo | |
| CO6251247A2 (es) | Imidazoquinolinas con propiedades inmuno-moduladoras | |
| AR087119A1 (es) | Composiciones plaguicidas y procesos relacionados | |
| AR105836A1 (es) | Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk | |
| CO5611128A2 (es) | Compuestos derivados de n-aril-2-oxazolidinona-5-carboxamida como agentes antibacteriales | |
| MX2009006286A (es) | Composiciones plaguicidas. | |
| ECSP055815A (es) | Composición para el tratamiento de la infección por virus flaviviridae | |
| AR051995A1 (es) | Derivados de tieno-piridina como intensificadores alostericos de gaba -b | |
| UY29266A1 (es) | Compuestos de piridazinona | |
| AR099495A1 (es) | Derivados de amida, antagonistas de orexina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |